Showing results (2221-2230 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|October 23, 2018
Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cellsNan Liu, Zhe Jin, Jing Zhang, et al.Investigational New Drugs|October 23, 2018
Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisoneGiandomenico Roviello, Roberto Petrioli, Alberto Bonetta, et al.Investigational New Drugs|April 19, 2017
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulationMagdalena Olbryt, Aleksandra Rusin, Izabela Fokt, et al.Investigational New Drugs|October 9, 2016
Evaluating the role of phase I expansion cohorts in oncologic drug developmentRobin E Norris, Mohadese Behtaj, Pingfu Fu, et al.Investigational New Drugs|July 1, 1989
Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicityJ L Abbruzzese, S Schmidt, M N Raber, et al.Investigational New Drugs|July 1, 1989
Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group StudyW P McGuire, J A Blessing, E Yordan, et al.Investigational New Drugs|July 1, 1989
Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council StudyM A Runge-Morris, M S Kies, E Vokes, et al.Investigational New Drugs|December 16, 2016
Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid speciesAlycen P Lundberg, Joshua M Francis, Malgorzata Pajak, et al.Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.Investigational New Drugs|February 1, 1991
Response rates, duration of response, and dose response effects in phase I studies of antineoplasticsD D Von Hoff, J TurnerPageof 372